Douglas S Daniels (Douglas Daniels)

Years Active: 2016-2024
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange, Jennifer A Roth, Douglas S Daniels, Virendar K Kaushik, Brian Hubbard, Karl Ziegelbauer, Todd R Golub
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature cancer (2024)
Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange, Jennifer A Roth, Douglas S Daniels, Virendar K Kaushik, Brian Hubbard, Karl Ziegelbauer, Todd R Golub
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature cancer (2024)
Colin W Garvie, Cara V Fraley, Nadine H Elowe, Elizabeth K Culyba, Christopher T Lemke, Brian K Hubbard, Virendar K Kaushik, Douglas S Daniels
Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor. Protein science : a publication of the Protein Society 25 (11) (2016)

Douglas S Daniels.css-eqlu8i{font-size:small;padding-left:4px;} (Douglas Daniels)